Seeking Alpha
17 Nov 2026, 17:52 UTC · 8h ago
Vivos Therapeutics, Inc. (VVOS) Q3 2026 Earnings Call Prepared Remarks Transcript
Impact · against what's priced in
Vivos Therapeutics beat Q3 2026 EPS and revenue estimates, providing a short-term positive signal. However, the nearly 5.5% year-over-year decline in revenue suggests a structural erosion that limits the long-term bullishness of the beat.
- VVOS+0.30
No priced-in read yet
- In context
The company reported a Q3 EPS of -$0.07, beating estimates by $0.25, and revenue of $6.41M, beating estimates by $939k, though revenue declined 5.44% year-over-year.
Read from the article alone

Search tags




